Showing 2787 results
-
Press release /Data analysis shows that preventing the symptoms of CSU (achieving complete control) improves overall health-related quality of life (HRQoL); including sleep and work productivity, among other…
-
Press release /Acquisition underscores Novartis commitment to using optogenetics-based therapies to restore vision to patients with advanced blindness Novartis gains one pre-clinical optogenetic AAV gene therapy…
-
Press release /Cette acquisition souligne l’engagement de Novartis à utiliser des thérapies basées sur l’optogénétique pour redonner la vue aux patients atteints de cécité avancéeNovartis acquiert un programme…
-
Press release /Mit der Übernahme unterstreicht Novartis ihre Absicht, das Sehvermögen von Patientinnen und Patienten mit einem fortgeschrittenen Sehverlust mittels Optogenetik wiederherzustellenNovartis sichert…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz stieg im dritten Quartal um +5% (kWk¹, +6% USD) Die Division Innovative Medicines wuchs um +7% (kWk, +8% USD)Starke Performance der…
-
Press release /Filings supported by pivotal ELARA trial, where treatment with Kymriah showed robust response rates and remarkable safety profile in adult patients with relapsed or refractory (r/r) follicular…
-
Press release /Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Novartis and Roche agree a bilateral transaction for the sale of Roche bearer shares held by Novartis for a total consideration of USD 20.7 billion…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KR Novartis und Roche vereinbaren bilaterale Transaktion zum Verkauf von Roche-Inhaberaktien im Besitz von Novartis zu einem Gesamtpreis von USD 20,7 Mrd. Der…
-
Press release /New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix® (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T…